Skip to content

Study · Randomized controlled trial · n = 68 · 2017

6 results

A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia.

Jarskog LF, Pedersen CA, Johnson JL, Hamer RM, Rau SW, Elliott T, Penn DL

Schizophrenia research13 Jan 2017Cited by 48 (Europe PMC)

PMID28094169 (opens in a new tab)PMCIDPMC5474129 (opens in a new tab)DOI10.1016/j.schres.2017.01.008 (opens in a new tab)PepBankPUB-28094169
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In outpatients with schizophrenia or schizoaffective disorder, oxytocin gave a modest advantage over placebo on one component of social functioning.

    In plain wordsIn people with schizophrenia, nasal oxytocin gave a small advantage over placebo on one part of social functioning.

    Peptide
    Oxytocin
    Outcome
    IncreaseComponent of social functioning
    Study

    n = 68

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    24 IU twice daily · intranasal · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Among secondary outcomes, there was a modest advantage for oxytocin over placebo on a component of social functioning
    1 context sentence
    Summary · context
    Sixty-eight eligible participants were randomized to oxytocin (24IU twice daily) or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In outpatients with schizophrenia or schizoaffective disorder, the placebo group outperformed the oxytocin group on the role-play task.

    In plain wordsIn people with schizophrenia, the placebo group did better than the nasal oxytocin group on a role-play task.

    Peptide
    Oxytocin
    Outcome
    DecreaseRole-play task performance
    Study

    n = 68

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    24 IU twice daily · intranasal · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    although there was also evidence that the placebo group outperformed the oxytocin group on the role-play task.
    1 context sentence
    Summary · context
    Sixty-eight eligible participants were randomized to oxytocin (24IU twice daily) or placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In outpatients with schizophrenia or schizoaffective disorder, intranasal oxytocin showed no advantage over placebo on social cognition.

    In plain wordsIn people with schizophrenia, nasal oxytocin did not improve social thinking more than placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeSocial cognition
    Study

    n = 68

    Comparator
    Placebo
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    24 IU twice daily · intranasal · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The study found no evidence for a differential advantage of oxytocin over placebo on social cognition.
    1 context sentence
    Summary · context
    Sixty-eight eligible participants were randomized to oxytocin (24IU twice daily) or placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In outpatients with schizophrenia or schizoaffective disorder, no between-group differences emerged on psychopathology measures in pre-specified comparisons.

    In plain wordsIn people with schizophrenia, nasal oxytocin did not change overall symptom measures compared with placebo in the planned comparisons.

    Peptide
    Oxytocin
    Outcome
    No significant changePsychopathology, pre-specified between-group comparisons
    Study

    n = 68

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    24 IU twice daily · intranasal · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    No between-group differences emerged on measures of psychopathology in pre-specified comparisons
    1 context sentence
    Summary · context
    Sixty-eight eligible participants were randomized to oxytocin (24IU twice daily) or placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In outpatients with schizophrenia or schizoaffective disorder, the oxytocin group had a significant within-group reduction in PANSS negative symptoms.

    In plain wordsIn people with schizophrenia, negative symptoms fell over time in the nasal oxytocin group.

    Peptide
    Oxytocin
    Outcome
    DecreasePANSS negative symptoms, within-group change
    Study

    n = 68

    Comparator
    Baseline
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    24 IU twice daily · intranasal · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    oxytocin showed significant within-group reduction in PANSS negative symptoms
    1 context sentence
    Summary · context
    Sixty-eight eligible participants were randomized to oxytocin (24IU twice daily) or placebo.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In the schizophrenia subgroup, oxytocin gave a significant between-group improvement in negative symptoms compared with placebo.

    In plain wordsIn the subgroup with schizophrenia, nasal oxytocin improved negative symptoms more than placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseNegative symptoms in schizophrenia subgroup, between-group
    Study

    n = 68

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    24 IU twice daily · intranasal · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    significant between-group improvement in negative symptoms in the schizophrenia subgroup.
    1 context sentence
    Summary · context
    Sixty-eight eligible participants were randomized to oxytocin (24IU twice daily) or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.